Predictive value of early and late residual 18F- fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 7, 2012, Pages 1117-1127

  Kobe, Carsten ^a,b   Scheffler, Matthias ^a,b   Holstein, Arne ^a,b   Zander, Thomas ^a,b   Nogova, Lucia ^a,b   Lammertsma, Adriaan A ^c   Boellaard, Ronald ^c   Neumaier, Bernd ^d   Ullrich, Roland T ^a,b,d   Dietlein, Markus ^a,b   Wolf, Jürgen ^a,b   Kahraman, Deniz ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b University of Cologne   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

FDG PET; FLT PET; Lung cancer; Residual uptake; Response assessment

Indexed keywords

3' FLUOROTHYMIDINE F 18; ERLOTINIB; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; CLINICAL ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; REVIEW; STANDARDIZED UPTAKE VALUE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIDEOXYNUCLEOSIDES; DISCRIMINANT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84862658340     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2118-8     Document Type: Review

References (16)

1. JO Prior M Montemurro MV Orcurto O Michielin F Luthi J Benhattar, et al. 2009 Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor J Clin Oncol 27 3 439 445 19064982 10.1200/JCO.2008.17.2742 1:CAS:528:DC%2BD1MXitF2gtr8%3D
2. L Mileshkin RJ Hicks BG Hughes PL Mitchell V Charu BJ Gitlitz, et al. 2011 Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib Clin Cancer Res 17 10 3304 3315 21364032 10.1158/1078-0432.CCR- 10-2763 1:CAS:528:DC%2BC3MXmtVGitrY%3D
3. T Zander M Scheffler L Nogova C Kobe W Engel-Riedel M Hellmich, et al. 2011 Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography J Clin Oncol 29 13 1701 1708 21422426 10.1200/JCO.2010.32.4939 1:CAS:528:DC%2BC3MXnslCjt74%3D
4. RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 122S 150S 19403881 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D
5. D Kahraman M Scheffler T Zander L Nogova AA Lammertsma R Boellaard 2011 Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET J Nucl Med 52 12 1871 1877 22065872 10.2967/jnumed.111.094458 1:CAS:528:DC%2BC38Xht1Skurw%3D
6. T Akhurst RJ Downey MS Ginsberg M Gonen M Bains R Korst, et al. 2002 An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer Ann Thorac Surg 73 259 264 11834020 10.1016/S0003-4975(01)03257-X
7. CJ Hoekstra SG Stroobants EF Smit J Vansteenkiste H van Tinteren PE Postmus, et al. 2005 Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer J Clin Oncol 23 33 8362 8370 16293866 10.1200/JCO.2005.01.1189
8. R Boellaard 2011 Need for standardization of 18F-FDG PET/CT for treatment response assessments J Nucl Med 52 Suppl 2 93S 100S 22144561 10.2967/jnumed.110.085662
9. R Boellaard NC Krak OS Hoekstra AA Lammertsma 2004 Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study J Nucl Med 45 9 1519 1527 15347719
10. NC Krak R Boellaard OS Hoekstra JW Twisk CJ Hoekstra AA Lammertsma 2005 Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial Eur J Nucl Med Mol Imaging 32 3 294 301 15791438 10.1007/s00259-004-1566-1
11. M van Heijl JM Omloo MI van Berge Henegouwen JJ van Lanschot GW Sloof R Boellaard 2010 Influence of ROI definition, partial volume correction and SUV normalization on SUV-survival correlation in oesophageal cancer Nucl Med Commun 31 7 652 658 20545013
12. R Boellaard MJ O'Doherty WA Weber FM Mottaghy MN Lonsdale SG Stroobants, et al. 2010 FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 1 181 200 19915839 10.1007/s00259-009-1297-4
13. T Denecke P Hundsdorfer D Misch IG Steffen S Schonberger C Furth, et al. 2010 Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters Eur J Nucl Med Mol Imaging 37 10 1842 1853 20505933 10.1007/s00259-010-1484-3
14. HJ Sohn YJ Yang JS Ryu SJ Oh KC Im DH Moon, et al. 2008 [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung Clin Cancer Res 14 22 7423 7429 19010859 10.1158/1078-0432.CCR-08- 0312 1:CAS:528:DC%2BD1cXhtlylurzM
15. AJ Buckler R Boellaard 2011 Standardization of quantitative imaging: the time is right, and 18F-FDG PET/CT is a good place to start J Nucl Med 52 2 171 172 21233179 10.2967/jnumed.110.081224
16. DS Binns A Pirzkall W Yu J Callahan L Mileshkin P Conti, et al. 2011 Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer Eur J Nucl Med Mol Imaging 38 4 642 650 21207024 10.1007/s00259-010-1665-0 1:CAS:528:DC%2BC3MXivFyksLs%3D